Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non Operating Income (2016 - 2022)

Enanta Pharmaceuticals (ENTA) has disclosed Other Non Operating Income for 11 consecutive years, with $393000.0 as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Other Non Operating Income fell 10.48% year-over-year to $393000.0, compared with a TTM value of -$746000.0 through Jun 2022, up 79.62%, and an annual FY2021 reading of -$27000.0, down 118.12% over the prior year.
  • Other Non Operating Income was $393000.0 for Q2 2022 at Enanta Pharmaceuticals, up from $291000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $2.4 million in Q2 2019 and bottomed at -$5.3 million in Q3 2020.
  • Average Other Non Operating Income over 5 years is $225266.7, with a median of $393000.0 recorded in 2022.
  • The sharpest move saw Other Non Operating Income plummeted 246.67% in 2018, then surged 4544.23% in 2019.
  • Year by year, Other Non Operating Income stood at -$100000.0 in 2018, then skyrocketed by 2176.0% to $2.1 million in 2019, then crashed by 67.39% to $677000.0 in 2020, then tumbled by 61.89% to $258000.0 in 2021, then surged by 52.33% to $393000.0 in 2022.
  • Business Quant data shows Other Non Operating Income for ENTA at $393000.0 in Q2 2022, $291000.0 in Q1 2022, and $258000.0 in Q4 2021.